Program
dupilumab
Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 529 open or running | phase 4since Jul 16, 2019 | Mar 9, 2011 | Feb 7, 2027phase 4 · NCT07905547 |
| Regeneron Pharmaceuticalsits history only | 404 open or running | phase 4since Dec 17, 2019 | Nov 10, 2009 | Apr 24, 2027phase 4 · NCT06572228 |
| Andover Eye Associatesits history only | 11 open or running | phase 2since Mar 2, 2020 | Mar 2, 2020 | none ahead |
Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Mar 9, 2011.
- Aug 31, 2022Phase 3 study in Chronic UrticariaNCT05526521 · 15 enrolled · United States, Canada, Japan
- Nov 13, 2022Phase 4 study in Dermatitis, AtopicNCT05624112 · 44 enrolled · China
- Dec 26, 2022Phase 4 study in Dermatitis, AtopicNCT05680298 · 34 enrolled · China
- Feb 3, 2023Phase 2 study in Colitis, UlcerativeNCT05731128 · 68 enrolled · United States, Argentina, Canada and more
- May 18, 2023Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT05878093 · 63 enrolled · China
- Jul 28, 20233 phase 1 studiesNCT05976386, NCT05976373, NCT05976360
- Aug 1, 2023Phase 4 study in Dermatitis, AtopicNCT05983068 · 48 enrolled · United States, United Kingdom
- Oct 19, 2023Phase 4 study in Eosinophilic EsophagitisNCT06101095 · 69 enrolled · United States, Brazil, Canada and more
- Dec 19, 2023Phase 3 study in Respiratory SoundsNCT06191315 · 90 planned · United States, Argentina, Brazil and more
- Feb 27, 2024Phase 3 study in Prurigo NodularisNCT06293053 · 18 planned · United States
- Nov 12, 20242 phase 3 studies in NeurodermatitisNCT06687980, NCT06687967
- Jun 27, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07053423 · 218 planned · United States, Argentina, Austria and more
- Jun 8, 2026Phase 1 study in Healthy VolunteersNCT07646548 · 40 enrolled · United States
- Oct 23, 2026Phase 4 study in Dermatitis, AtopicNCT07905547 · 56 planned
Ahead
- Feb 7, 2027Primary completion: phase 4 study in Dermatitis, AtopicNCT07905547
- Mar 16, 2027Primary completion: phase 4 study in AsthmaNCT05097287
- Apr 29, 2027Primary completion: phase 4 study in Dermatitis, AtopicNCT05983068
- Jun 2, 2027Primary completion: phase 3 study in PruritusNCT05263206
TargetBeta
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| TQH2722 | Sino Biopharmaceutical | phase 3 | 7 |
| SHR-1819 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 52 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07905547Dermatitis, Atopic | 4 | Not yet recruiting | Feb 7, 2027 | 56 |
| NCT07646548Healthy Volunteers · United States | 1 | Completed | Sep 30, 2026 | 40 |
| NCT07053423Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more | 4 | Recruiting | Dec 23, 2028 | 218 |
| NCT06687980Neurodermatitis · United States, Argentina, Belgium and more | 3 | Completed | Jun 8, 2026 | 138 |
| NCT06687967Neurodermatitis · United States, Argentina, Canada and more | 3 | Completed | Jun 8, 2026 | 142 |
| NCT06293053Prurigo Nodularis · United States | 3 | Recruiting | Oct 28, 2027 | 18 |
| NCT06191315Respiratory Sounds · United States, Argentina, Brazil and more | 3 | By invitation | Dec 21, 2028 | 90 |
| NCT06101095Eosinophilic Esophagitis · United States, Brazil, Canada and more | 4 | Active, not recruiting | Nov 5, 2025 | 69 |
| NCT05983068Dermatitis, Atopic · United States, United Kingdom | 4 | Active, not recruiting | Apr 29, 2027 | 48 |
| NCT05976386Healthy Volunteers · United States | 1 | Completed | Sep 24, 2021 | 182 |
| NCT05976373Healthy Volunteers · United States | 1 | Completed | Mar 30, 2015 | 38 |
| NCT05976360Healthy Volunteer · United States | 1 | Completed | Jan 17, 2015 | 38 |
| NCT05878093Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Completed | Sep 6, 2024 | 63 |
| NCT05731128Colitis, Ulcerative · United States, Argentina, Canada and more | 2 | Active, not recruiting | May 13, 2026 | 68 |
| NCT05680298Dermatitis, Atopic · China | 4 | Completed | Dec 22, 2023 | 34 |
| NCT05624112Dermatitis, Atopic · China | 4 | Completed | Jan 25, 2024 | 44 |
| NCT05526521Chronic Urticaria · United States, Canada, Japan | 3 | Completed | Nov 11, 2024 | 15 |
| NCT05263206Pruritus · United States, Argentina, Canada and more | 3 | Recruiting | Jun 2, 2027 | 284 |
| NCT05097287Asthma · United States, Belgium, Brazil and more | 4 | Active, not recruiting | Mar 16, 2027 | 1,339 |
| NCT05049122Chronic Rhinosinusitis With Nasal Polyps · Japan | 4 | Completed | Dec 21, 2022 | 25 |
| NCT04998604Asthma · United States, Belgium, Canada and more | 4 | Completed | Oct 16, 2024 | 360 |
| NCT04823130Dermatitis, Atopic · United States, Germany | 4 | Completed | Jun 30, 2022 | 54 |
| NCT04718870Dermatitis, Atopic · United States, United Kingdom | 4 | Completed | Sep 7, 2022 | 41 |
| NCT04684524Allergic Fungal Sinusitis · United States, Argentina, Canada and more | 3 | Completed | Dec 14, 2024 | 62 |
| NCT04681729Cold Urticaria · United States, Argentina, Canada and more | 3 | Completed | Feb 2, 2023 | 82 |
| NCT04678882Dermatitis, Atopic · Japan | 3 | Completed | Dec 14, 2021 | 62 |
| NCT04678856Sinusitis · United States, Argentina, Belgium and more | 2 | Completed | Nov 14, 2023 | 71 |
| NCT04502862Asthma · United States, Argentina, Canada and more | 4 | Completed | Oct 3, 2023 | 202 |
| NCT04456673Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | Feb 28, 2024 | 935 |
| NCT04447417Dermatitis, Atopic · United States, Canada | 4 | Completed | Jun 17, 2021 | 52 |
| NCT04400318Asthma · United States, Bulgaria, Denmark and more | 4 | Completed | Jun 26, 2023 | 109 |
| NCT04202679Neurodermatitis · United States, Canada, Chile and more | 3 | Completed | Aug 30, 2021 | 160 |
| NCT04183335Neurodermatitis · United States, Argentina, China and more | 3 | Completed | Nov 12, 2021 | 151 |
| NCT04180488Chronic Urticaria · United States, Argentina, Canada and more | 3 | Completed | Aug 1, 2024 | 397 |
| NCT04033367Dermatitis, Atopic · United States, Australia, France and more | 4 | Completed | Oct 6, 2021 | 188 |
| NCT03930732Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | Feb 8, 2023 | 939 |
| NCT03912259Dermatitis, Atopic · China | 3 | Completed | Feb 14, 2020 | 165 |
| NCT03782532Asthma · China, India | 3 | Completed | May 21, 2022 | 486 |
| NCT03620747Asthma · United States, Argentina, Belgium and more | 3 | Completed | Feb 18, 2022 | 393 |
| NCT03560466Asthma · United States, Argentina, Australia and more | 3 | Completed | Apr 1, 2025 | 378 |
| NCT02948959Asthma · United States, Argentina, Australia and more | 3 | Completed | Aug 26, 2020 | 408 |
| NCT02912468Nasal Polyps · United States, Bulgaria, Czechia and more | 3 | Completed | Jul 5, 2018 | 276 |
| NCT02898454Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) · United States, Argentina, Australia and more | 3 | Completed | Aug 27, 2018 | 448 |
| NCT02573233Asthma · United States, Canada, Denmark and more | 2 | Completed | Jan 3, 2018 | 42 |
| NCT02528214Asthma · United States, Argentina, Belgium and more | 3 | Completed | Sep 20, 2017 | 210 |
| NCT02414854Asthma · United States, Argentina, Australia and more | 3 | Completed | Jul 29, 2017 | 1,902 |
| NCT02134028Asthma · United States, Argentina, Australia and more | 3 | Completed | Oct 11, 2019 | 2,282 |
| NCT01920893Nasal Polyps · United States, Belgium, Spain and more | 2 | Completed | Nov 2014 | 60 |
| NCT01854047Asthma · United States, Argentina, Australia and more | 2 | Completed | Nov 2014 | 776 |
| NCT01537653Healthy · Japan | 1 | Completed | Oct 2012 | 32 |
| NCT01537640Healthy · United States | 1 | Completed | Jul 2012 | 30 |
| NCT01312961Asthma · United States | 2 | Completed | Oct 2012 | 104 |
How it is read
Names in the registry
- “Dupilumab”, 55 entries
- “Dupilumab SAR231893”, 13 entries
- “dupilumab”, 10 entries
- “Dupilumab (SAR231893)”, 5 entries
- “REGN668”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 32 studies
- Asthma, 17 studies
- Eosinophilic Esophagitis, 5 studies
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.